The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma., PMID:40509933
The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma., PMID:40509933
Mechanistic Insights into Anti-Nectin4-VcMMAE-Induced Ocular Toxicity: From Cellular Uptake Pathways to Molecular Modification., PMID:40507807
Mechanistic Insights into Anti-Nectin4-VcMMAE-Induced Ocular Toxicity: From Cellular Uptake Pathways to Molecular Modification., PMID:40507807
Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy., PMID:40496844
Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy., PMID:40496844
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer., PMID:40474033
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer., PMID:40474033
Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions., PMID:40433388
Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions., PMID:40433388
Ecology and evolutionary trajectories of morbilliviruses in Neotropical bats., PMID:40425830
Ecology and evolutionary trajectories of morbilliviruses in Neotropical bats., PMID:40425830
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale., PMID:40421891
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale., PMID:40421891
Assessment of trophoblast cell-surface antigen 2 (TROP2) and nectin-4 expression in choriocarcinoma., PMID:40414312
Assessment of trophoblast cell-surface antigen 2 (TROP2) and nectin-4 expression in choriocarcinoma., PMID:40414312
Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies., PMID:40403357
Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies., PMID:40403357
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer., PMID:40401457
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer., PMID:40401457
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373
Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4., PMID:40380880
Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4., PMID:40380880
Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions., PMID:40361519
Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions., PMID:40361519
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study., PMID:40288679
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study., PMID:40288679
Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer., PMID:40252843
Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer., PMID:40252843
Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report., PMID:40235861
Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report., PMID:40235861
Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances., PMID:40225697
Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances., PMID:40225697
High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy., PMID:40215164
High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy., PMID:40215164
Nectin-4 expression patterns and therapeutics in oncology., PMID:40209851
Nectin-4 expression patterns and therapeutics in oncology., PMID:40209851
Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas., PMID:40198857
Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas., PMID:40198857
Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers., PMID:40187750
Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers., PMID:40187750
A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma., PMID:40160871
A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma., PMID:40160871
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer., PMID:40129250
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer., PMID:40129250
Theranostic implications of Nectin-4 oncoprotein in gynecologic cancers: A review., PMID:40101551
Theranostic implications of Nectin-4 oncoprotein in gynecologic cancers: A review., PMID:40101551
Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management., PMID:40086591
Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management., PMID:40086591
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734
A novel and promising therapeutic approach for treating pancreatic cancer: Nectin‑4‑targeted antibody‑drug conjugates alone or combined with autophagy inhibitors., PMID:40017149
A novel and promising therapeutic approach for treating pancreatic cancer: Nectin‑4‑targeted antibody‑drug conjugates alone or combined with autophagy inhibitors., PMID:40017149
Understanding the Toxicity Profile of Approved ADCs., PMID:40006625
Understanding the Toxicity Profile of Approved ADCs., PMID:40006625
225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer., PMID:39978811
225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer., PMID:39978811
Nectin-4: A promising prognostic marker and therapeutic target in cancer., PMID:39939077
Nectin-4: A promising prognostic marker and therapeutic target in cancer., PMID:39939077
Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin., PMID:39928161
Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin., PMID:39928161
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium., PMID:39890750
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium., PMID:39890750
Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations., PMID:39890303
Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations., PMID:39890303
Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma., PMID:39877564
Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma., PMID:39877564
Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions., PMID:39858014
Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions., PMID:39858014
Antibody-drug conjugates in urothelial carcinoma: current status and future., PMID:39844537
Antibody-drug conjugates in urothelial carcinoma: current status and future., PMID:39844537
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer., PMID:39801278
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer., PMID:39801278
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives., PMID:39764422
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives., PMID:39764422
NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA., PMID:39763905
NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA., PMID:39763905
Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis., PMID:39754977
Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study., PMID:39748460
Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study., PMID:39748460
[Pathology and molecular pathology of carcinoma of the penis]., PMID:39694900
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review., PMID:39626158
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review., PMID:39626158
[Muscle-invasive and metastatic urothelial carcinoma from a pathological point of view]., PMID:39603252
[Muscle-invasive and metastatic urothelial carcinoma from a pathological point of view]., PMID:39603252
Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis., PMID:39598456
Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis., PMID:39598456
Assessing the expression of Nectin-4 in solid tumors by immunohistochemistry - what do we know?, PMID:39582282
Assessing the expression of Nectin-4 in solid tumors by immunohistochemistry - what do we know?, PMID:39582282
Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects., PMID:39577073
Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects., PMID:39577073
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China., PMID:39530574
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China., PMID:39530574
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer., PMID:39513959
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer., PMID:39513959
For research use only. Not for human or drug use.
